Compare ACADIA Pharmaceuticals Inc. (ACAD) vs VanEck Australian Floating Rate ETF (FLOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs VanEck Australian Floating Rate ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while VanEck Australian Floating Rate ETF trades at $50.93. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | FLOT | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Sector/Thematic |
52-Week High | $29.41 | $51.09 |
52-Week Low | $20.06 | $50.72 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLOT, the iShares Floating Rate Bond ETF, trades at $50.93, showing minimal daily movement. The technical outlook is bearish based on moving averages, though oscillators are neutral. Recent news highlights its role as a potential hedge against rising interest rates, with a focus on high credit quality and a 4.0% SEC yield. Dividend payments are consistent, with recent distributions around $0.17-$0.18 per share.
The outlook for FLOT is cautiously positive if the Federal Reserve raises rates, as its floating rate structure could benefit income growth. Risks include credit quality deterioration and persistent inflation without Fed action. Analyst sentiment is generally neutral, viewing it as a stable short-term cash alternative rather than a growth vehicle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →
